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Cadmium (Cd) is a widespread nephrotoxic 
food contaminant that accumulates and has 
a particularly long biological half-life in the 
liver and kidney (Amzal et al. 2009; Järup 
and Åkesson 2009). More recently, Cd was 
proposed to possess endocrine-disruptive 
properties. Several well-charac  terized estro-
genic responses were induced in rodents 
after intra  peritoneal injection of low doses of 
Cd (Johnson et al. 2003). Effects included 
increased uterine weight, luminal epithelium 
height, hyperplasia and hypertrophy of the 
endometrial lining, induction of uterine pro-
gesterone receptor expression, and enhanced 
formation of side branches, and alveolar buds 
in the mammary gland. Many of the effects 
have been confirmed by other groups, however 
with higher doses (Alonso-Gonzalez et al. 2007; 
Höfer et al. 2009; Zhang et al. 2007). 
Estrogen, because of its proliferative effects, 
is a key factor in the etiology of breast and endo-
metrial cancer (Persson 2000). Consequently, 
pollutants that mimic the effects of estrogen have 
been suggested to contribute to the high inci-
dence of hormone-related cancers in Western 
populations (Davis et al. 1993; Safe 2004). The 
observed associations between long-term dietary 
Cd exposure and endometrial cancer incidence 
(Åkesson et al. 2008) and between urinary Cd 
and risk of breast cancer (McElroy et al. 2006) 
support this hypothesis. However, little is 
known about the possible mechanisms of action 
involved in the estrogenic responses associated 
with Cd exposure.
The classical mode of action of estrogens 
is mediated by transcriptional actions of the 
nuclear estrogen receptors, ERα and ERβ. 
In the classical estrogen signaling pathway, 
these receptors regulate transcription through 
direct interaction with specific DNA binding 
sites—estrogen-responsive elements (EREs)—
present in the promoter regions of target genes 
(Edwards 2005; Nilsson et al. 2001). Estrogens 
can also signal through a non  classical genomic 
pathway, where the ERs modulate transcrip-
tion by tethering to other transcription factors, 
such as Sp1 and activator protein-1 (AP-1), 
instead of binding directly to DNA. The 
rapid biochemical and physiological effects 
of estrogens indicate that an alternative path-
way, acting at the level of the plasma mem-
brane (plasma membrane–associated signaling) 
should also be considered. In this process, var-
ious cytosolic kinase signaling pathways are 
activated (Acconcia and Kumar 2006; Fu and 
Simoncini 2008; Levin and Pietras 2008).
Several in vitro studies have shown that 
Cd can activate ERα, increase ERα-mediated 
cell prolifera  tion, induce mitogenesis, and 
have mutagenic properties (Brama et al. 2007; 
Jin et al. 2003; Misra et al. 2002; Siewit et al. 
2010; Slebos et al. 2006, Stoica et al. 2000). In 
a recent study, Benbrahim-Tallaa et al. (2009) 
also showed that Cd malignantly transforms 
normal ER-negative human breast epithelial 
cells. Furthermore, in breast cancer cell lines, 
Cd has been shown to cause rapid activation 
of extracellular signal-regulated kinase (Erk)1/2 
and Akt, suggesting membrane-  associated 
estrogen signaling (Liu et al. 2008). In con-
trast, some in vitro estrogenicity assays showed 
no Cd-induced activity (Le Guevel et al. 2000; 
Silva et al. 2006; Vetillard and Bailhache 2005).
Because of the inconsistent and inconclu-
sive findings on the estrogenicity of Cd both 
in vitro and in vivo and because of the possible 
link to the risk of hormonal cancers in humans, 
we investigated the estrogenic responses of Cd 
in mice using a slightly modi  fied version of the 
rodent utero  trophic bio  assay [Organisation for 
Economic Co-operation and Development 
(OECD) 2007]. This bioassay is a widely used 
in vivo system used to detect the estrogenic 
properties of chemicals and has been applied 
in many studies. To assess the tissue-specific 
activation of classical genomic estrogen signal-
ing, we exposed transgenic immature female 
ERE-luciferase mice (Lemmen et al. 2004) to 
cadmium chloride (CdCl2) or ethinyl  estradiol 
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Ba c k g r o u n d: Cadmium (Cd), a ubiquitous food contaminant, has been proposed to be an 
  endocrine disruptor by inducing estrogenic responses in vivo. Several in vitro studies suggested that 
these effects are mediated via estrogen receptors (ERs). 
oB j e c t i v e: We performed this study to clarify whether Cd-induced effects in vivo are mediated via 
classical ER signaling through estrogen responsive element (ERE)-regulated genes or if other signal-
ing pathways are involved.
me t h o d s : We investigated the estrogenic effects of cadmium chloride (CdCl2) exposure in vivo 
by applying the Organisation for Economic Co-operation and Development (OECD) rodent 
uterotrophic bioassay to transgenic ERE-luciferase reporter mice. Immature female mice were 
injected subcutaneously with CdCl2 (5, 50, or 500 µg/kg body weight) or with 17α-ethinylestradiol 
(EE2) on 3 consecutive days. We examined uterine weight and histology, vaginal opening, body and 
organ weights, Cd tissue retention, activation of mitogen-activated protein kinase (MAPK) pathways, 
and ERE-dependent luciferase expression. 
re s u l t s: CdCl2 increased the height of the uterine luminal epithelium in a dose-dependent manner 
without increasing the uterine wet weight, altering the timing of vaginal opening, or affecting the 
luciferase activity in reproductive or non  reproductive organs. However, we observed changes in the 
phosphorylation of mouse double minute 2 oncoprotein (Mdm2) and extracellular signal-regulated 
kinase (Erk1/2) in the liver after CdCl2 exposure. As we expected, EE2 advanced vaginal opening 
and increased uterine epithelial height, uterine wet weight, and luciferase activity in various tissues. 
co n c l u s i o n: Our data suggest that Cd exposure induces a limited spectrum of estrogenic responses 
in vivo and that, in certain targets, effects of Cd might not be mediated via classical ER signaling 
through ERE-regulated genes.
key w o r d s : cadmium, endocrine disruption, estrogen-like effects, metalloestrogens, estrogen recep-
tors, uterus. Environ Health Perspect 118:1389–1394 (2010).  doi:10.1289/ehp.1001967 [Online 
4 June 2010]Ali et al.
1390  v o l u m e  118 | n u m b e r 10 | October 2010  •  Environmental Health Perspectives
(EE2). In addition, we assessed the activation 
of mitogen-activated protein kinase (MAPK) 
pathways. Our main objectives were to provide 
new knowledge on the mecha  nisms involved 
in the estrogenic effects of Cd in vivo and to 
examine the sensitivity of these effects at Cd 
exposure levels of relevance for health risk 
assessment considerations.
Materials and Methods
Animals. In this study we used immature mice 
carrying an estrogen-responsive reporter gene 
construct (3xERE-TATA-luciferase) consist-
ing of trimerized ERE coupled to a minimal 
TATA-box driving the expression of luciferase, 
described in detail by Legler et al. (1999) 
and Lemmen et al. (2004). The animals in 
our study were derived from the β-globin 
insulated ERE-luc line INS7 (Lemmen 
et al. 2004). The animal experiments were 
performed at the animal department of the 
University of Turku under license numbers 
1592/05 and ESLH-2007-03984. Animals 
used in this study were treated humanely and 
with regard for alleviation of suffering. All 
experimental animals were kept under stan-
dard housing conditions on a 12:12-hr light/
dark cycle at 22 ± 1°C and 50–60% relative 
humidity. Animals had free access to purified 
AIN-93G rodent diet [Special Diet Services 
(SDS), Whitham, Essex, UK] (Reeves et al. 
1993) with slight modifications: Soy oil was 
replaced with rape seed oil to eliminate all 
possible residual phyto  estrogens from the diet 
(Penttinen-Damdimopoulou et al. 2009).
Subcutaneous injection of CdCl2 and 
EE2. Nineteen-day-old female mice weighing 
7–9 g, randomly selected for each treatment 
group, received CdCl2 (Sigma, St. Louis, 
MO, USA) dissolved in sterile phosphate-
buffered saline (PBS) at 5 (n = 6), 50 (n = 6), 
and 500 µg/kg body weight (BW) (n = 5) 
per day for 3 consecutive days via subcutane-
ous (SC) injections. Control animals (n = 5) 
were injected with sterile PBS. We used EE2 
(Sigma) dissolved in corn oil (50 µg/kg BW, 
SC) as a positive control (n = 5).
Tissue collection. One day after the last 
injection, (the fourth day of the experiment), 
the 22-day-old mice were examined for vag-
inal opening, euthanized by carbon dioxide 
asphyxia  tion, and weighed. Subsequently, 
whole blood was drawn by heart puncture, and 
tissues [brain, pituitary gland, mammary gland, 
white adipose tissue (WAT), ovary, uterus, 
vagina, liver, kidney, heart, and lungs] were 
collected into micro  centrifuge tubes, snap-fro-
zen in liquid nitrogen, and stored at –80°C 
until analysis. We recorded organ weights for 
uterus, liver, and kidney. For Cd analysis, one 
kidney and a piece of liver were placed sepa-
rately into sterile acid-washed micro  centrifuge 
tubes (StarLab, Ahrensburg, Germany) and 
kept on dry ice before storage at –80°C. One 
horn of the uterus was fixed in 10% formalin 
(Oy FF-Chemicals AB, Haukipudas, Finland) 
overnight and preserved in 70% ethanol 
(Kemetyl AB, Huddinge, Sweden) for histo-
logical evalua  tion. 
Cd analysis. We analyzed Cd concentration 
in liver and kidney, the main organs of accu-
mulation, using inductively coupled plasma 
mass spectrometry (Agilent 7500ce; Agilent 
Technologies, Waldbronn, Germany) with 
a collision/reaction cell system autosampler 
(Cetac ASX-510; Cetac Technologies, Omaha, 
NE, USA), an integrated sample introduction 
system, and a MicroMist nebulizer (Agilent 
Technologies, Waldbronn, Germany) in 
quartz (Kippler et al. 2009). Digestion of tis-
sue samples was performed with a Milestone 
ultraCLAVE II microwave digestion system 
(EMLS, Leutkirch, Germany). Approximately 
0.5 g sample was mixed with 2 mL nitric acid 
(65% suprapur; Merck, Darmstadt, Germany) 
and 3 mL deionized water, and then digested 
at 250°C for 30 min in the autoclave. For qual-
ity control, we analyzed the following reference 
samples: NBS bovine liver 1577 (National 
Bureau of Standards, Washington, DC, USA), 
CRM 185 bovine liver, CRM 186 pig kidney, 
Seronorm MR4206 blood (BCR, Brussels, 
Belgium), and Seronorm 0503109 blood 
(SERO AS, Billingstad, Norway); results for 
all reference samples were at their target value. 
The limit of detection (LOD) was 0.004 ng/g, 
calculated as mean of digested blanks + 3 SDs. 
All the measured concentrations were above 
the calculated LOD.
Leuciferas activity measurements. We meas-
ured luciferase activity in individual samples as 
previously described by Penttinen et al. (2007). 
Relative light units (RLUs) were calculated as 
  RLU
CPSC PS
Proteinsample
sample background
=
-
,  [1]
where CPS is counts per second, CPSbackground 
and CPSsample  are the average CPS val-
ues measured from each plate before and 
after the luciferase reaction, respectively, and 
Proteinsample refers to the protein concentration 
measured in each sample. 
Briefly, frozen liver, kidney, lungs, brain, 
heart, mammary gland, and WAT samples 
were minced by hammering on a cold metal 
surface, and immediately transferred to 12-mL 
tubes together with lysis buffer [25 mM 
Tris-acetate (pH 7.8), 1.5 mM EDTA, 10% 
glycerol, 1% Triton-X, 2 mM dithio  threitol 
(Sigma) containing Complete Mini-Protease 
Inhibitor Tablets (Roche Diagnostics GmbH, 
Penzberg, Germany)]. Pituitary gland, uterus, 
vagina, and ovary tissue samples were homog-
enized directly in lysis buffer with a micro-
pestle. Homogenates were centrifuged at 4°C, 
4,000 rpm, for 30 min and supernatants were 
collected into sterile micro  centrifuge tubes. 
Luciferase activity was measured using the 
BioThema Luciferase Assay Kit (BioThema, 
Haninge, Sweden) in 96-well plates (Greiner, 
Frickenhausen, Germany). Luminescence was 
recorded with a Victor2 1420 Multilabel ana-
lyzer (PerkinElmer, Turku, Finland), and pro-
tein contents were measured using Bradford 
assay reagents (Bio-Rad Protein Assay; Bio-Rad, 
Hercules, CA, USA) on a Shimadzu UV-1601 
spectro  photometer (Shimadzu, Kyoto, Japan). 
Concentrations were determined by compari-
son with bovine serum albumin (BSA) stan-
dards (BSA Fraction V; Sigma). 
Western blot analysis of pErk, pAkt, and 
phospho‑mouse double minute 2 oncoprotein 
(pMdm2) in liver. We quantified the protein 
contents in frozen liver homogenates using 
Coomassie Plus Protein Assay Reagent (Pierce, 
Täby, Sweden). The samples were subjected 
to SDS-PAGE, and the separated proteins 
were transferred to a polyvinylidene difluoride 
membrane (Bio-Rad) and subsequently probed 
with primary antibodies {pMdm2 (Ser166) 
from Cell Signaling Technology (Danvers, 
MA, USA); and phospho-Erk [Tyr204 (E-4), 
sc-7383], phospho-Akt (Ser473) sc-7985, 
and cyclin-dependent kinase 2 [Cdk2 (M2), 
Figure 1. Tissue Cd concentration (mean ± SD) in 
the liver and kidney after SC exposure to CdCl2, 
EE2, or PBS for 3 consecutive days. 
*p < 0.05, and #p < 0.001, compared with the PBS-treated 
control by Dunnett’s multiple comparison test. 
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Table 1. Body, liver, and kidney weights (mean ± SD) after SC exposure to CdCl2, EE2, or PBS for 
3 consecu  tive days. 
Body weight (g) Organ weight (g/kg BW)
Treatment n Day 18 Day 22 Percent increase Liver Kidney
PBS control 5 8.44 ± 1.0 10.12 ± 0.91 16.6 50.8 ± 1.8 14.7 ± 0.6
CdCl2 (5 µg/kg) 6 8.58 ± 0.4 10.32 ± 0.38 16.8 50.4 ± 1.9 14.8 ± 1.0
CdCl2 (50 µg/kg) 6 8.61 ± 0.5 10.08 ± 0.62 14.6 49.3 ± 6.2 14.8 ± 0.7
CdCl2 (500 µg/kg) 5 8.66 ± 0.4 10.26 ± 0.44 15.6 51.6 ± 1.2 14.6 ± 0.7
EE2 (50 µg/kg) 5 8.50 ± 0.9 10.22 ± 0.99 16.8 56.9 ± 2.1* 14.6 ± 1.1
*p < 0.05 compared with the PBS control group by Dunnett’s multiple comparison test.Estrogen-like effects of cadmium
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sc-163] from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA)} and then secondary antibod-
ies [goat anti-rabbit IgG (sc-2004) and goat 
anti-mouse IgG (sc-2005) from Santa Cruz 
Biotechnology]. Cdk2 was used as a loading 
control. The results were visualized using the 
ECL detection kit (Amersham GE Healthcare 
Bio-sciences AB, Uppsala, Sweden). The den-
sitometric analysis was performed using ImageJ 
version 1.41o software (National Institutes of 
Health, Bethesda, MD, USA; http://rsbweb.
nih.gov/ij/index.html). 
Histological evaluation of the uterus. 
Sections of paraffin-embedded uterine tis-
sues (6 µm) were mounted on SuperFrost 
Plus slides (Menzel-Gläzer, Braunschweig, 
Germany) followed by clearing, rehydration, 
and staining with hematoxylin and eosin 
(Fischer et al. 2006). All sections (five or six 
per animal) were examined under a Diaplan 
light microscope (Leitz, Wetzlar, Germany), 
and photos were taken for computerized 
image analysis. The height of luminal epithe-
lium (micrometers) was measured at 10 differ-
ent locations in two sections per animal to get 
an average value of luminal epithelium height.
Statistical analysis. Unless stated otherwise, 
all reported values are expressed as mean ± SD. 
For luciferase measure  ments, data are expressed 
as median and range. We used one-way analy-
sis of variance to compare the effect among dif-
ferent treatment groups. For values that were 
statistically significant, we applied Dunnett’s 
multiple comparison test to make post hoc 
comparisons between the means of control 
and treatment groups. Luciferase activity 
data were log transformed before statistical   
analysis. Differences were considered signifi-
cant at p < 0.05 for two-tailed tests.
Results
Vaginal opening and body, liver, and kidney 
weights. To examine the onset of puberty, we 
monitored the vaginal opening after EE2 and 
CdCl2 treatments. All EE2-treated animals 
displayed vaginal opening on the last day of 
the experiment (22 days of age), indicating 
advanced onset of puberty. On the same day, 
no vaginal opening was observed in any of the 
CdCl2-treated or PBS control animals. 
To investigate the signs of general toxic-
ity after CdCl2 exposure, we measured body 
weights and relative liver and kidney weights. 
These weights were not altered in the CdCl2- 
or EE2-treated animals compared with PBS 
controls (Table 1), with one exception: EE2 
caused an increase in relative liver weight. 
Cd concentrations in liver and kidney. To 
verify the effectiveness of dosing and to meas-
ure the internal dose of Cd after treatment, 
we analyzed liver and kidney Cd concentra-
tions. Cd concentrations in liver and kidney 
samples increased in a dose-dependent man-
ner (Figure 1). Among all treatment groups, 
the highest concentrations were found in liver 
compared with kidneys (about two to three 
times higher in liver than in kidneys). The Cd 
concentrations in liver were between 58 and 
2,833 ng/g wet weight, whereas in kidneys the 
Cd concentrations from 36 to 1,109 ng/g wet 
weight. EE2  -treated and PBS control animals 
showed very low Cd concentrations both in 
liver and in kidneys.
Luciferase activity. We measured luciferase 
activity in reproductive and non  reproductive 
organs to detect ER-mediated ERE-regulated 
gene expression (Figure 2). After EE2 expo-
sure, uterus, vagina, pituitary gland, liver, kid-
ney, and brain showed significantly increased 
luciferase activities compared with PBS controls 
(negative control). No significant alterations in 
luciferase activity were detected in any of the 
CdCl2-treated groups; however, non  significant 
decreases in luciferase activity were observed 
in several organs after exposure to the lowest 
dose of CdCl2 (5 µg/kg BW). Data on lung, 
heart, and WATs are not reported because 
luciferase activity levels in these tissues were 
not distinguishable from background in most 
of the vehicle- and CdCl2-treated animals. One 
of the EE2-treated animals showed very low 
levels of luciferase activity, which indicates a 
non  functional reporter. However, because the 
genotype of this mouse was confirmed, it was 
included in the statistical analysis.
Western blot analysis of pErk, pAkt, and 
pMdm2 in liver. Western blot analysis of liver 
homogenates was performed to gain knowl-
edge on the involvement of intra  cellular sig-
naling pathways. Data showed significantly 
Figure 2. Tissue-specific expression of luciferase activity in uterus, ovary, vagina, mammary gland, pitu-
itary gland, liver, kidney, and brain after SC exposure to CdCl2, EE2, or PBS for 3 consecutive days. Lines 
inside boxes represent median, boxes indicate 25th and 75th percentiles, and whiskers represent range. 
*p < 0.05, **p < 0.01, and #p < 0.001 compared with the PBS-treated control by Dunnett’s multiple comparison test. 
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increased phosphorylation of Mdm2 at Ser166 
in the high-dose CdCl2-treated (500 µg/kg 
BW) and EE2-treated animals, whereas no 
changes in phosphorylation of Akt at Ser473 
was observed in CdCl2- or EE2-treated groups. 
Phosphorylation of Erk at Tyr204 was signifi-
cantly increased after exposure to 5 or 50 µg of 
CdCl2/kg BW compared with the PBS control 
(Figure 3).
Uterine wet weight and histology. Results 
of the uterotrophic assay showed that uterine 
wet weight was significantly increased after 
EE2 treatment (Figure 4). However, there 
was no increase in uterine wet weight in the 
CdCl2-treated animals, except that two of six 
animals in the low-dose group showed numeri-
cally higher (2.71 and 3.07 g/kg BW) uter-
ine wet weights compared with PBS controls 
(mean, 1.53g/kg BW). Histological evalua-
tion of uterine tissues showed that the height 
of the luminal epithelium was significantly 
increased in a dose-dependent manner after 
CdCl2-treatment. EE2 treatment also caused 
a significant increase in the height of uter-
ine epithelium compared with PBS controls 
(Figure 5A–F).
Discussion
In this study we investigated the estrogenicity 
of Cd in transgenic ERE-luciferase reporter 
mice by applying the OECD uterotrophic 
bioassay protocol. We obtained only limited 
evidence for estrogen-like effects by Cd—an 
increase in the height of the uterine luminal 
epithelium and changes in the phosphorylation 
of Erk1/2 and Mdm2 in the liver. Surprisingly, 
we detected no induction of the classical 
genomic ERα signaling pathway after Cd 
exposure, based on the lack of uterine growth 
and the lack of induction of the ERE-regulated 
luciferase reporter gene.
The luminal epithelial height and uterine 
wet weight are well-established end points for 
evaluating estrogenicity of chemicals (Branham 
et al. 1993, Diel et al. 2002; OECD 2007). In 
our examination of the histology of the uteri, 
we found a dose-dependent increase in the 
height of the luminal epithelium, which was 
almost doubled in the animals treated with 
500 µg CdCl2/kg BW and four times higher in 
the EE2-treated mice compared with PBS con-
trols; this is consistent with previous studies in 
rats (Höfer et al. 2009; Johnson et al. 2003; 
Zhang et al. 2007). We found no increase in 
uterine wet weight in animals treated with 
50 or 500 µg CdCl2/kg BW; however, there 
were indications of an increase in uterine wet 
weight after treatment with 5 µg CdCl2/kg 
BW. In that group, two of six animals had 
uterine wet weights similar to those of the 
EE2-treated mice. Similar partial responses 
in CdCl2-treated animals have been recorded 
earlier in rats (Höfer et al. 2009). Our find-
ings on uterine wet weight response after acute 
CdCl2 exposure support those of Zhang et al. 
(2007) and Höfer et al. (2009) at the doses 
investigated, but are in contradiction to those 
previously reported by Johnson et al. (2003). 
However, considering the differences in ani-
mal model and the experimental conditions 
used in previous studies, the dose range of 
Cd that could induce uterine weight increase 
is still under debate. Previously, Johnson 
et al. (2003) reported that uterine wet weight 
increased 1.7 times when ovariectomized rats 
were administered a single intra  peritoneal (IP) 
injection of 5 µg CdCl2/kg BW. In another 
study using ovariectomized rats, the uterine 
weight increased after IP injection of 1,200 µg 
Cd2+/kg BW for 3 days, whereas no increase 
was observed with 120 µg Cd2+/kg BW 
(Zhang et al. 2007). More recently, Höfer 
et al. (2009) reported that uterine wet weight 
increased after a single IP injection of 500 or 
2,000 µg CdCl2/kg BW; relative to controls, 
wet weight increased 1.2 and 1.4 times, respec-
tively. However, no response was observed at 
lower doses.
Estrogen-induced responses in the uterus 
are mediated both by classical ERE-dependent 
and non  classical ERE-independent ER signal-
ing. Studies using gene-modified mice sug-
gest that direct binding of ERα to DNA (i.e., 
classical estrogen signaling) is required for the 
uterine growth response (Ahlbory-Dieker et al. 
2009; O’Brien et al. 2006), whereas the uter-
ine luminal epithelium can respond to estro-
gen treatment even in the absence of classical 
signaling (O’Brien et al. 2006). We found that 
CdCl2 treatment did not affect uterine weight 
in the treated animals, nor did it induce the 
ERE-regulated reporter gene. These observa-
tions suggest that Cd might not activate classi-
cal estrogen signaling in the mouse uterus. 
However, CdCl2 treatment dose-dependently 
increased the height of the luminal epithe-
lium. This suggests that Cd still possesses some 
estrogen-like activity in the uterus. Because 
the data imply an absence of classical signal-
ing, non  classical estrogen signaling should 
be considered as an alternative mechanism. 
In non  classical signaling, estrogens promote 
ERα tethering to other transcription factors 
such as AP-1, Sp1, and nuclear factor-κB. 
Furthermore, estrogens can trigger rapid, non-
genomic, membrane-associated effects. These 
types of estrogen activities cannot be detected 
in our mouse model in terms of reporter gene 
activation. Interestingly, recent in vitro work 
suggested that Cd can promote non  classical 
transcriptional activation of ERα in vitro 
(Siewit et al. 2010). Furthermore, Cd pro-
motes phosphorylation of Erk1/2, a marker 
of membrane-associated estrogen signaling, 
in the rat uterus in vivo (Zhang et al. 2007). 
It remains to be elucidated whether Cd can 
Figure 3. Western blots and densitometric analysis of phosphorylated (p) Erk, Akt, and Mdm2 in liver homo-
genates after SC exposure to CdCl2, EE2, or PBS for 3 consecutive days. (A) Representative Western blots. 
Densitometric analysis of Mdm2(Ser166) (B), Akt(Ser473) (C), and Erk(Tyr204) (D). Data were normalized 
against Cdk2, and the signal for the PBS vehicle control was set to 100%. Results represent mean ± SD. 
*p < 0.05, **p < 0.01, and #p < 0.001, compared with PBS-treated controls by Dunnett’s multiple comparison test. 
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Figure 4. Body weight–adjusted uterine wet 
weights after SC exposure to CdCl2, EE2, or PBS for 
3 consecutive days. Data shown are mean ± SD. 
#p < 0.001 compared with PBS-treated controls by Dunnett’s 
multiple comparison test. 
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trigger ERα tethering or membrane-associated 
signaling in the mouse uterus and whether this 
activity would lead to the thickening of the 
luminal epithelium.
We investigated the effects of CdCl2 on 
classical ER signaling by analyzing ERE-
regulated luciferase expression. As expected, our 
data showed significant increases in luciferase 
activity after SC exposure to the positive con-
trol EE2. However, we did not find any signifi-
cant changes after SC injection of up to 500 µg 
CdCl2/kg BW. Instead of an increase, there 
was a nonsignificant decrease in the luciferase 
activity in most of the organs at relatively low 
doses of CdCl2 (5 µg/kg BW), which could 
reflect a weak antagonistic response. This obser-
vation is in line with a recently reported down- 
regulation of C3 mRNA expression (an indica-
tor of estrogenic activity) after IP injection of 
a single dose of 0.05–50 µg CdCl2/kg BW in 
rats (Höfer et al. 2009). Furthermore, regard-
ing interaction of Cd with ER, Le Guevel et al. 
(2000) hypothe  sized that this interaction can 
occur only after the ERα has been activated 
by an agonist and that this inter  action pre-
vents ERα from binding to DNA and sub-
sequently inhibits its transcriptional activity. 
This hypothe  sis was also supported by findings 
reported by Silva et al. (2006). Our findings 
on the ERE-regulated luciferase expression in 
response to CdCl2 exposure suggest a similar, 
antagonistic behavior of Cd interaction with 
ER in an in vivo setting.
Rapid phosphorylation of Erk1/2 MAPK 
in in vitro cell systems has been reported as an 
indicator of membrane-associated ER signal-
ing (Liu et al 2008; Santen et al. 2002; Zang 
et al. 2009; Zivadinovic and Watson 2005). 
Activation of Erk1/2 is a widely used end point 
to reflect E2-induced non  genomic effects in 
a variety of in vitro cell systems (Filardo et al. 
2000; 2002; Pedram et al. 2006; Razandi et al. 
2003a, 2003b, 2004). Cd has been shown to 
activate Erk in MCF-7 cells in vitro and in rat 
uterus in vivo (Liu et al. 2008; Zhang et al. 
2007); however, not all studies support these 
observations (Silva et al. 2006). Prompted by 
reports on the ERE-independent estrogen activ-
ity of Cd (Siewit et al. 2010: Zhang et al. 2007) 
and by our observations of the estrogen-like 
ERE-independent activity of Cd in the uterus, 
we explored the possible involvement of non-
classical ER signaling in Cd-mediated responses 
in our mouse model by analyzing pErk, pAkt, 
and pMdm2 contents in liver homogenates. We 
found a significant inversely dose-dependent 
activation of ERK1/2 after CdCl2 exposure. 
Compared with PBS controls, Erk phosphory-
lation was 3.5 times higher in animals exposed 
to 5 µg CdCl2/kg BW and 2.5 times higher 
in those exposed to 50 µg CdCl2/kg BW, but 
it was unchanged in response to EE2. This 
finding, together with the non  response in 
luciferase activity, suggests that Cd-induced 
phosphorylation of Erk is not mediated by 
classi  cal ER signaling. Akt is considered a 
counterpart of Erk1/2 that could prevent cells 
from under  going apoptosis induced by certain 
chemical or physical agents. However, we did 
not find any change in the amount of pAkt in 
either CdCl2- or EE2-treated groups.
Mdm2 is a negative regulator of the tumor 
suppressor p53, thus blocking p53 transcrip-
tional activity and targeting p53 for protea-
some-mediated degradation. Mdm2 interacts 
with various cellular proteins and is over-
expressed in many human malignancies (Zang 
and Wang 2000). ER signaling has been shown 
to activate Mdm2, and Mdm2 is involved in 
the regulation of ERα turnover (Duong et al. 
2007). We observed an activation of Mdm2 
after CdCl2 (dose dependent) and EE2 treat-
ment, indicating that Cd-induced estrogen-like 
responses may be mediated via non  classical 
ER signaling and may contribute to promot-
ing malignancies. Mdm2 phosphorylation 
induced by other environmental toxicants leads 
to attenuation of p53 response (Pääjärvi et al. 
2005). However, further studies are required to 
clarify any role of Mdm2 phosphorylation in 
Cd induced toxicity.
Cd induces estrogenic responses differently 
in different studies, which may be because Cd 
uptake is strongly influenced by the route of 
exposure (Elsenhans et al. 1994; Höfer et al. 
2009). In the present study, as expected, Cd 
contents in liver and kidney increased dose 
dependently after SC exposure to CdCl2, 
which reflects the effectiveness of dosing via 
SC injection. Internal dose in our study was 
similar to that reported by Zheng et al. (1996) 
after SC injection and by Höfer et al. (2009) 
after IP injection. Höfer et al. (2009) reported 
that Cd concentrations in uterus were simi-
lar to those in liver. In contrast, the observed 
Cd-mediated estrogen-like responses are differ-
ent between studies. For instance, Höfer et al. 
(2009) reported that uterine wet weight and 
Figure 5. Height of the uterine luminal epithelium (µm) after SC exposure to CdCl2, EE2, or PBS for 3 consecu-
tive days. (A–E) Representative photomicrographs of uterine tissue sections stained with hematoxylin and 
eosin (40×). (F) Quantitative evaluation of the uterine epithelium height (micrometers). Results represent 
mean ± S.D. 
**p < 0.01, and #p < 0.001 compared with the PBS-treated control by Dunnett’s multiple comparison test. 
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luminal epithelial height did not respond to oral 
adminis  tration of 0.5 and 4mg CdCl2/kg BW, 
but the same dosing regimen increased uterine 
C3 mRNA expression 54 and 276 times, respec-
tively. With regard to the route of exposure, 
Johnson et al. (2003) reported that C3 mRNA 
expression was 12 times higher in rats after IP 
injection of 5 µg CdCl2/kg BW, whereas Höfer 
et al. (2009) observed a clear decrease in C3 
mRNA expression in rats with the same dose 
and route of exposure. This opposite response 
by Cd with the same dose and route of expo-
sure in rats puts forward some new questions 
on its mode of action. Factors other than dose 
and mode of exposure, such as species/strain 
sensitivity, timing of exposure, age, and basal 
diet are likely to contribute to the net effects 
seen in the different studies.
Conclusions
The present study shows that in the imma-
ture mouse model, Cd may induce a limited 
spectrum of estrogen-like effects in the uterus 
and liver without showing stimulation of ERE-
mediated activation of ERα signaling (i.e., uter-
ine weight gain or induction of ERE-regulated 
luciferase activity). Our findings suggest the 
involvement of other intra  cellular signaling 
pathways (i.e., regulation of non-ERE target 
genes; activation of membrane-associated ERα, 
G-protein coupled receptors, or growth factors, 
or cross-talk among them) in the biological 
activity of Cd. Further studies are needed to 
understand the molecular mechanisms involved 
in the estrogen-like activity of Cd and to clar-
ify the conflicting data obtained in different 
in vivo and in vitro models used to investigate 
the estrogenicity of Cd. Our study provides 
some support for the association between 
Cd and the risk of hormone-related cancer 
observed in epidemiological studies (Åkesson 
et al. 2008; McElroy et al. 2006). Because all 
people have a lifelong exposure to Cd via food 
(Järup and Åkesson 2009; Satarug et al. 2010), 
this finding is of public health concern.
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